BRAF and cancer: Indeed, the oncogenic activation of BRAF drives the inappropriate activation of ERK signaling and the deregulation of cell proliferation [5], and is responsible for the inhibition of the mitochondrial apoptotic pathway [6–8], the latter being consistent with the apoptosis-resistant phenotype of BRAF-driven cancer cells.